Phen concerns weigh on Qsiva's EU approval but US roll-out unaffected
This article was originally published in Scrip
Executive Summary
Vivus left its mid-September meeting with the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) feeling pretty certain that the company's weight loss drug Qsiva (phentermine/topiramate) would not be recommended for EMA approval.